Prevalence of NTRK gene fusions in a large cohort of Japanese patients with lung cancer
Atsushi Nakamura(Sendai Kousei Hospital), Kōichi Goto(National Cancer Center Hospital East), Hisashi Mitsufuji(Kitasato University), Hibiki Udagawa(National Cancer Center Hospital East), Akira Hirata(Waseda University), Masato Shingyoji(Chiba Cancer Center), Yuki Kataoka(Kyoto University), Atsushi Horiike(The Cancer Institute Hospital), Daiki Ogawara(Nagasaki University), Kiyotaka Yoh(National Cancer Center Hospital East), Shoichi Kuyama(Iwakuni Medical Center), Isamu Okamoto(Kyushu University Hospital), Yoshihiro Miyata(Hiroshima University), Shunichi Sugawara(Sendai Kousei Hospital), Y. Ohe, Toyoaki Hida(Saitama International Medical Center), Terufumi Kato(Taipei Veterans General Hospital), Shingo Matsumoto(National Cancer Center Hospital East), Ryota Kanemaru(Juntendo University), Sho Saeki(Kumamoto University Hospital)
Cited by 3
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
|Journal of Clinical Oncology|2013|3.2k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k